Results 11 to 20 of about 182,433 (270)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy

Case Reports in Pulmonology, 2015
Hepatitis C virus infection is the leading cause of chronic liver disease in the United States of America. Pegylated interferon α and ribavirin combination is the mainstay of treatment. Severe pulmonary toxicities are rarely reported.
Amit Chopra, Creticus Marak, Narendrakumar Alappan, Chang Shim   +3 more
doaj   +2 more sources

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population [PDF]

Kidney & Blood Pressure Research, 2015
Background/Aims: Hepatitis C virus infection remains prevalent among patients undergoing long-term haemodialysis and has a detrimental impact on survival in this population.
Mario Espinosa, Jesùs Hernàndez, Maria Dolores Arenas, Fernando Carnicer, Carlos Caramelo, Fabrizio Fabrizi   +5 more
doaj   +2 more sources

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C

Case Reports in Gastroenterology, 2009
The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy.
Elson Vidal Martins Jr., Ana Karla Gaburri, Debora Gaburri, Angelo Sementilli   +3 more
doaj   +2 more sources

Thyrotoxicosis With Pegylated Interferon Alfa-2b [PDF]

Archives of Dermatology, 2010
Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease.
Lowndes, SA, Asher, R, Middleton, MR
openaire   +3 more sources

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C

Journal of Nepal Medical Association, 2011
Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients.
T Kanda, O Yokosuka
doaj   +2 more sources

Nucleos(t)ide analogue therapy combined with pegylated interferon α-2b guided by the GOLDEN prediction model for functional cure of chronic hepatitis B: study protocol (GIFT project). [PDF]

BMJ Open
Chai S, Jiang J, Wang C, He Y, Jia X, Xi Q, Jing F, Chang L, Zhang W, Guo Y, Du F, Feng J, Chai Y, Cao Y, Li F, Zhang L, Chen S, Wang Y, Lin Y, Cao H, Zhang Y, Liang Y, Li F, Hao Y, Gao X, Li H, Zhang Y, Kang W.   +27 more
europepmc   +2 more sources

Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study. [PDF]

Int J Gen Med
Yang WY, Lin Y, Lin C, Pan C, Ye YM.
europepmc   +3 more sources

Dynamics of spatiotemporal pharmacological models for hepatitis B virus infection under lamivudine and pegylated interferon alfa-2b therapies. [PDF]

BMC Infect Dis
Tchioffo BR, Mvogo A, Abiama PE.
europepmc   +2 more sources

Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B. [PDF]

Front Immunol
Zhu L, Peng F, Pi D, Lu J.
europepmc   +3 more sources

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. [PDF]

Front Cell Infect Microbiol
Wen C, He T, Zha G, Li A, Wang Z, Zhou Z, Cai D, Zhang D, Peng M, Shi X, Ren H.   +10 more
europepmc   +3 more sources